Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accuray’s radiation oncology business is packed with regulatory nuance—each 10-K page covers FDA clearances, global supply chains, and service-contract margins. Finding R&D spend or tracking when executives trade shares should not require hours with spreadsheets. That’s why our SEC filings hub brings Accuray insider trading Form 4 transactions and every other disclosure into one streamlined view.
Stock Titan’s AI reads the fine print for you. Open an Accuray quarterly earnings report 10-Q filing and our algorithms instantly surface backlog changes, CyberKnife unit shipments, and reimbursement commentary. Get Accuray Form 4 insider transactions real-time alerts, side-by-side with revenue trend graphs. Whether you’re understanding Accuray SEC documents with AI for due diligence or need an Accuray annual report 10-K simplified, we translate technical jargon into clear business drivers.
Every filing type is here and searchable: 8-Ks for product-recall updates—see “Accuray 8-K material events explained”—DEF 14A for Accuray proxy statement executive compensation, and of course Form 4 for Accuray executive stock transactions Form 4. Use our AI-powered summaries to compare quarter-over-quarter margin shifts, monitor clinical-trial timelines, and flag warranty reserve changes. With comprehensive coverage, real-time EDGAR pulls, and plain-English insights, you’ll move from document download to actionable perspective in minutes while enjoying Accuray SEC filings explained simply and fast Accuray earnings report filing analysis.
Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.
The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.
Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.
The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
What does Accuray Incorp specialize in?
What are some key technologies developed by Accuray?
How do Accuray's systems improve cancer treatment?
Who are the primary customers of Accuray?
How does Accuray maintain its position in a competitive market?
What benefits does real-time tracking technology offer?
How is Accuray contributing to global cancer care?
